GSK to acquire U.S.-based BELLUS Health for $14.75 per share
April 18, 2023 at 02:33 AM EDT
GSK said the deal will provide access to camlipixant, a treatment for refractory chronic cough currently in phase III development.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|